EMA (EU)
GUIDANCE FINAL
Draft guideline on clinical investigation of medicinal products for the treatment of migraine and cluster headache - Revision 2
Published: 9/10/2026Detected: 9/10/2026
Summary preview
Sets out EMA expectations for the clinical investigation strategy and pivotal trial methodology for medicinal products intended for acute and prophylactic treatment of migraine and cluster headache, including key design…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
- First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
- Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
- PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
- SPOR and XEVMPD status update webinar - Q4 202610/7/2026